Previous 10 | Next 10 |
Vor Biopharma press release ( NASDAQ: VOR ): Q2 GAAP EPS of -$0.58 beats by $0.08 . Cash, cash equivalents and investments were $151.1 million as of June 30, 2022, which is anticipated to fund operations into the first quarter of 2024. For further details see: ...
Initial clinical data for patients treated with Vor Bio’s engineered HSC candidate VOR33 on track for Q4 2022 In-house manufacturing facility in Cambridge, MA operational in Q4 2022 Data presented at EHA successfully demonstrates in-vivo engraftment of multiplex e...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Gainers: Ocean Bio-Chem OBCI +117%. Exela Technologies XELA +47%. Boxed BOXD +44%. Revlon REV +39%. Vivakor (VIVK) +22%. Omeros Corporation (OMER) +21%. Vor Biopharma (VOR) +21%. Wave Life Sciences WVE +18%. Siyata Mobile (SYTA) +18%. Visionary Education Technology (V...
Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia Dual edited hematopoietic stem and progenitor cells persisted long-term post engraftment, wit...
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Jefferies Healthcare Conference Presentation date: Wednesday,...
Vor Biopharma press release (NASDAQ:VOR): Q1 GAAP EPS of -$0.61. Cash, cash equivalents and investments were $181.6 million as of March 31, 2022, which is anticipated to fund operations into the fourth quarter of 2023. For further details see: Vor Biopharma GAAP EPS of -$0.61
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022 Data presented at Keystone Symposia demonstrates significant advancement of novel multiplex editing platform In-house manufacturing facility in Cambridge, MA operational i...
Goldman Sachs has initiated Vor Biopharma (NASDAQ:VOR) with a neutral rating as the early-stage blood cancer therapy developer still has a lot to prove. The firm has a $6 price target (~7% upside based on Tuesday's close). Analyst Andrea Tan said that the technology behind the company's lead ...
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that two abstracts have been accepted for poster presentations at the Keystone Symposia Precision Genome Engineering meeting, held April 27 to Ma...
News, Short Squeeze, Breakout and More Instantly...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...